| 产品详情 |
| Edit |   |
|---|
| Product Name | SP-2509 |
|---|
| Description | Purity ≥95% (HPLC). LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP2509 is a selective and reversible LSD1 inhibitor with an IC50 of 10nM. SP2509 demonstrates a high specificity for LSD1, with no effect on MAOi. Synonyms: (E)-N'-(1-(5-chloro-2- hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, SP-2509 |
|---|
| Size | 1mg, 5mg, 10mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | (E)-N'-(1-(5-chloro-2- hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, SP-2509 |
|---|
| Gene, Accession, CAS # | CAS: 1423715-09-6 |
|---|
| Catalog # | 215891 |
|---|
| Price | |
|---|
| Order / More Info | SP-2509 from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|